These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6101957)

  • 21. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
    Azadkhan AK; Truelove SC; Aronson JK
    Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of Azulfidine/Salazopyrin in healthy humans and in patients with chronic inflammatory bowel diseases].
    Van Hees PA
    Z Gastroenterol Verh; 1981 Jun; 19():7-14. PubMed ID: 6168136
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
    Ashworth M; Arthur M; Turmer AD; Smith PR
    Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the intestinal flora in the acetylation of sulfasalazine metabolites.
    Dull BJ; Salata K; Goldman P
    Biochem Pharmacol; 1987 Nov; 36(21):3772-4. PubMed ID: 2890356
    [No Abstract]   [Full Text] [Related]  

  • 27. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oro-caecal transit time in man assessed by the sulfasalazine/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine.
    Dhôte R; Leglise P; Bergmann JF; Conort O; Caulin C
    Fundam Clin Pharmacol; 1992; 6(8-9):383-5. PubMed ID: 1363408
    [No Abstract]   [Full Text] [Related]  

  • 29. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
    Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
    J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of salicylazosulphapyridine and sulphapyridine in plasma using high-performance liquid chromatography.
    Lanbeck K; Lindström B
    J Chromatogr; 1978 Jul; 154(2):321-4. PubMed ID: 28333
    [No Abstract]   [Full Text] [Related]  

  • 33. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
    Azad Khan AK; Truelove SC
    Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma.
    Shaw PN; Sivner AL; Aarons L; Houston JB
    J Chromatogr; 1983 May; 274():393-7. PubMed ID: 6135701
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of the colon in the metabolism of salicylazosulphapyridine.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
    [No Abstract]   [Full Text] [Related]  

  • 36. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?
    Fischer C; Klotz U
    Ther Drug Monit; 1980; 2(2):153-8. PubMed ID: 6132473
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic studies of sulfapyridine acetylation in the rabbit.
    Lima JJ; Salzer LJ; Morrison G; Devine TA
    Biopharm Drug Dispos; 1982; 3(2):185-9. PubMed ID: 7104465
    [No Abstract]   [Full Text] [Related]  

  • 39. Placental and mammary transfer of sulphasalazine.
    Khan AK; Truelove SC
    Br Med J; 1979 Dec; 2(6204):1553. PubMed ID: 43760
    [No Abstract]   [Full Text] [Related]  

  • 40. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
    van Hogezand RA; van Hees PA; Zwanenburg B; van Rossum JM; van Tongeren JH
    Gastroenterology; 1985 Mar; 88(3):717-22. PubMed ID: 2857146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.